Dual-Antibody Cocktail Shows Effectiveness In COVID-19 Animal Models: Reuters
In mice and hamster study, COVID-19 therapies comprising two types of antibodies were found to be effective against…
Roche’s Alzheimer’s Antibody Reduces Associated Biomarkers In Subset Of AD Patients, Study Shows
Experimental anti-amyloid antibodies from Eli Lilly & Co (NYSE:LLY) and Roche Holding AG’s (OTC:RHHBY) failed to improve symptoms of Alzheimer’s disease (AD)…
Biden Administration Devotes Over $3.2B For Development Of Oral Antiviral Therapies For COVID-19: CNBC
Officials on Thursday announced that the Biden Administration plans to invest more than $3.2 billion in developing antiviral medicines to…
Eli Lilly To Test Injectable Migraine Med Against Biohaven’s Oral Nurtec In Head-To-Head Study
Eli Lilly And Co (NYSE:LLY) will conduct a head-to-head study comparing once-monthly injectable Emgality (galcanezumab-gnlm) with Biohaven Pharmaceutical Holding Co Ltd’s (NYSE:BHVN) Nurtec…
JP Morgan Maintains Overweight on Eli Lilly, Raises Price Target to $260
JP Morgan analyst Chris Schott maintains Eli Lilly (NYSE:LLY) with a Overweight and raises the price target from $240 to $260.
Lilly Announces Head-To-Head Study Comparing Once-Monthly Emgality With Every-Other-Day Nurtec ODT For Preventive Treatment Of Migraine
To advance the science of migraine treatment and aid the understanding of calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) compared to oral CGRP receptor antagonists in the prevention of migraine, Eli
Goldman Sachs Maintains Buy on Eli Lilly, Raises Price Target to $270
Goldman Sachs analyst Terence Flynn maintains Eli Lilly (NYSE:LLY) with a Buy and raises the price target from $252 to $270.
The Latest Barron’s Picks And Pans: DocuSign, UPS, Taiwan Semiconductor And More
The cover story in this weekend's Barron's examines how teenage traders are shaking up the market.
Other featured articles discuss which drugmakers benefit from a new market, why it is time to buy momentum stocks and how to safely hunt for yield.
Eli Lilly’s Internal Probe Clears Its COVID-19 Drug Plant; Memo Says Company Did Not Make False Statements: Reuters
Eli Lilly and Co (NYSE:LLY) revealed last month that the U.S. Department of Justice (DOJ) issued a subpoena into its manufacturing…